ORIC Pharmaceuticals, Inc.

NasdaqGS:ORIC Stock Report

Market Cap: US$579.4m

ORIC Pharmaceuticals Future Growth

Future criteria checks 0/6

ORIC Pharmaceuticals's earnings are forecast to decline at 8.4% per annum while its annual revenue is expected to grow at 69.6% per year. EPS is expected to grow by 1.9% per annum. Return on equity is forecast to be -42.7% in 3 years.

Key information

-8.4%

Earnings growth rate

1.9%

EPS growth rate

Biotechs earnings growth27.6%
Revenue growth rate69.6%
Future return on equity-42.7%
Analyst coverage

Good

Last updated19 Dec 2024

Recent future growth updates

Recent updates

We Think ORIC Pharmaceuticals (NASDAQ:ORIC) Can Afford To Drive Business Growth

Dec 12
We Think ORIC Pharmaceuticals (NASDAQ:ORIC) Can Afford To Drive Business Growth

Here's Why We're Not Too Worried About ORIC Pharmaceuticals' (NASDAQ:ORIC) Cash Burn Situation

Aug 21
Here's Why We're Not Too Worried About ORIC Pharmaceuticals' (NASDAQ:ORIC) Cash Burn Situation

ORIC Pharmaceuticals Stock: Too Early To Justify This Valuation

Jul 29

ORIC Pharma: ORIC-114 Advancement To Phase 1b Expansion Study Could Yield Value

Jul 17

We're Hopeful That ORIC Pharmaceuticals (NASDAQ:ORIC) Will Use Its Cash Wisely

May 08
We're Hopeful That ORIC Pharmaceuticals (NASDAQ:ORIC) Will Use Its Cash Wisely

ORIC Pharmaceuticals: Mid-2024 Prostate Cancer Program Update Could Lead To Gains

Mar 13

We're Not Very Worried About ORIC Pharmaceuticals' (NASDAQ:ORIC) Cash Burn Rate

Jan 18
We're Not Very Worried About ORIC Pharmaceuticals' (NASDAQ:ORIC) Cash Burn Rate

We Think ORIC Pharmaceuticals (NASDAQ:ORIC) Can Afford To Drive Business Growth

Sep 27
We Think ORIC Pharmaceuticals (NASDAQ:ORIC) Can Afford To Drive Business Growth

ORIC Pharmaceuticals (NASDAQ:ORIC) Is In A Good Position To Deliver On Growth Plans

Jun 14
ORIC Pharmaceuticals (NASDAQ:ORIC) Is In A Good Position To Deliver On Growth Plans

Companies Like ORIC Pharmaceuticals (NASDAQ:ORIC) Are In A Position To Invest In Growth

Jan 24
Companies Like ORIC Pharmaceuticals (NASDAQ:ORIC) Are In A Position To Invest In Growth

ORIC Pharmaceuticals: Poster Child For The Current Downturn In Biotech

Oct 14

Is ORIC Pharmaceuticals (NASDAQ:ORIC) In A Good Position To Deliver On Growth Plans?

Oct 08
Is ORIC Pharmaceuticals (NASDAQ:ORIC) In A Good Position To Deliver On Growth Plans?

ORIC Pharmaceuticals GAAP EPS of -$0.51 beats by $0.09

Aug 11

ORIC Pharmaceuticals (NASDAQ:ORIC) Is In A Good Position To Deliver On Growth Plans

Jun 24
ORIC Pharmaceuticals (NASDAQ:ORIC) Is In A Good Position To Deliver On Growth Plans

We're Hopeful That ORIC Pharmaceuticals (NASDAQ:ORIC) Will Use Its Cash Wisely

Mar 08
We're Hopeful That ORIC Pharmaceuticals (NASDAQ:ORIC) Will Use Its Cash Wisely

We Think ORIC Pharmaceuticals (NASDAQ:ORIC) Can Afford To Drive Business Growth

Nov 23
We Think ORIC Pharmaceuticals (NASDAQ:ORIC) Can Afford To Drive Business Growth

We Think ORIC Pharmaceuticals (NASDAQ:ORIC) Can Afford To Drive Business Growth

Aug 05
We Think ORIC Pharmaceuticals (NASDAQ:ORIC) Can Afford To Drive Business Growth

ORIC Pharmaceuticals EPS beats by $0.04

May 06

Here's Why We're Not Too Worried About ORIC Pharmaceuticals' (NASDAQ:ORIC) Cash Burn Situation

Apr 16
Here's Why We're Not Too Worried About ORIC Pharmaceuticals' (NASDAQ:ORIC) Cash Burn Situation

We're Hopeful That ORIC Pharmaceuticals (NASDAQ:ORIC) Will Use Its Cash Wisely

Jan 01
We're Hopeful That ORIC Pharmaceuticals (NASDAQ:ORIC) Will Use Its Cash Wisely

Oric Pharma starts expansion phase of mid-stage solid tumor study with ORIC-101

Dec 21

Oric Pharma prices stock offering at $23

Nov 13

Earnings and Revenue Growth Forecasts

NasdaqGS:ORIC - Analysts future estimates and past financials data (USD Millions)
DateRevenueEarningsFree Cash FlowCash from OpAvg. No. Analysts
12/31/202611-191-150-1649
12/31/2025N/A-160-123-12711
12/31/2024N/A-127-97-8911
9/30/2024N/A-120-110-109N/A
6/30/2024N/A-111-100-100N/A
3/31/2024N/A-102-96-95N/A
12/31/2023N/A-101-87-86N/A
9/30/2023N/A-93-78-77N/A
6/30/2023N/A-93-78-76N/A
3/31/2023N/A-90-75-73N/A
12/31/2022N/A-89-77-75N/A
9/30/2022N/A-91-78-76N/A
6/30/2022N/A-85-71-69N/A
3/31/2022N/A-85-69-67N/A
12/31/2021N/A-79-60-60N/A
9/30/2021N/A-84-62-61N/A
6/30/2021N/A-91-59-59N/A
3/31/2021N/A-81-53-52N/A
12/31/2020N/A-74-46-45N/A
9/30/2020N/A-54-35-35N/A
6/30/2020N/A-35-31-30N/A
3/31/2020N/A-30-27-26N/A
12/31/2019N/A-27-24-24N/A
12/31/2018N/A-21-21-21N/A

Analyst Future Growth Forecasts

Earnings vs Savings Rate: ORIC is forecast to remain unprofitable over the next 3 years.

Earnings vs Market: ORIC is forecast to remain unprofitable over the next 3 years.

High Growth Earnings: ORIC is forecast to remain unprofitable over the next 3 years.

Revenue vs Market: ORIC is forecast to have no revenue next year.

High Growth Revenue: ORIC is forecast to have no revenue next year.


Earnings per Share Growth Forecasts


Future Return on Equity

Future ROE: ORIC is forecast to be unprofitable in 3 years.


Discover growth companies

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2024/12/22 06:13
End of Day Share Price 2024/12/20 00:00
Earnings2024/09/30
Annual Earnings2023/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .

Analyst Sources

ORIC Pharmaceuticals, Inc. is covered by 13 analysts. 11 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Colleen KusyBaird
Prakhar AgrawalCantor Fitzgerald & Co.
Yigal NochomovitzCitigroup Inc